Introduction
Bleeding during anticoagulant therapy is a problem with profound implications for the management of thromboembolic disease. At a population level, it is a source of morbidity and mortality which diminishes the overall benefits of anticoagulation. For the individual patient, bleeding can be life-threatening or fatal, clearly outweighing any preconceived benefits of anticoagulants. In contrast, risks of bleeding often weigh heavily in considering anticoagulation for the patient, and may lead to the withholding of a therapy which would have been beneficial. Assessment of risks of bleeding is therefore important in formulating the risk-benefit equation which helps target therapy appropriately.
Overall benefits of anticoagulation may be extrapolated from randomized clinical trials in a particular condition to the individual patient. For example, recent studies confirmed the efficacy of warfarin in preventing embolic events in non-rheumatic atrial fibrillation!-<l with acceptably low rates of haemorrhage, and there is renewed support for long-term anticoagulation after myocardial infarction." By extending the number of patients for whom anticoagulants may be appropriate, such studies do not necessarily © Edward Arnold 1995 aid individual decision making. Trial subjects are often rather different from the usual patient population perhaps by reason of age or by application of strict exclusion criteria regarding perceived contraindications to the therapy in question. In addition, haemorrhagic events are not evenly distributed throughout the study group: they are categorical data whose 'value' can range from minimal to absolute.
Thus, the clinician must evaluate the individual risks and benefits in the light of some notional overall benefit suggested by such trials. In this respect, studies analysing the influence of certain treatment or patient factors on rates of bleeding may be valuable in modifying assessments of risk for the individual. Such factors are most commonly derived from a combination of randomized controlled trials and subgroup analysis of cohorts undergoing anticoagulation; the limitations of these approachs will be discussed later.
This paper reviews the overall risks of bleeding during anticoagulation with regard to both frequency and severity, and examines the evidence supporting certain features as markers or predictors of increased bleeding risk. Their identification may improve risk. assessment and thereby appropnate use of anticoagulants, In addition, identification of risk factors may allow risks to be modified, This review is primarily concerned with therapeutic or 'formal' anticoagulation, that is the use of vitamin K antagonists (which we have referred to as warfarin as that is what is almost always used in the UK) and heparin in doses designed to prolong traditional in vitro measures of coagulation such as the prothrombin time (PT) and the activated partial thromboplastin time (APTT). Primary thromboprophylaxis with lower doses of anticoagulants, and the use of other anti thrombotic agents will only be discussed where relevant to the central issue.
Heparin
The predominant uses of heparin are in the prevention of venous thrombosis by subcutaneous injection of low doses, and in the treatment of venous thromboembolism or ischaemic heart disease with higher 'therapeutic' doses. Heparin can produce or exacerbate bleeding by three mechanisms. It interacts with platelets and may prolong the bleeding time," as well as increasing blood vessel permeability. 9 Its main action is to accelerate inhibition of several activated coagulation factors by antithrombin III, of which inhibition of thrombin (IIa) and factor Xa is probably most important for inhibition of thrombosis, as well as risk of bleeding. The effect on factors IX and XI is probably much less significant. The low molecular weight heparins appear to possess relatively more anti-Xa activity than anti-Ila activity when compared to standard unfractionated heparin.
Bleeding risks with therapeutic heparin -duration of therapy Absolute bleeding frequencies have been calculated by analysing inception cohort studies of patients treated with heparin for the usual indications. Rates of haemorrhage varied widely, even considering the treatment of venous thromboembolic disease alone, from 1% to 33% between the studies.t''-!' Landefeld and Beyth have recently analysed the overall rates of bleeding from eight inception cohort studies, and found rates of fatal, major, and major or minor bleeding of, respectively, 0.4%, 6% and 16%, with average daily frequencies of bleeding of 0.05%,0.8% and 2%.12 It is apparent, therefore, that the cumulative risks of bleeding with heparin increase with increasing duration of therapy.
Since there are few placebo-controlled trials of therapeutic heparin, it is difficult to assess the extent of bleeding attributable to heparin therapy rather than any underlying disease. One metaanalysis of prophylactic heparin compared with placebo indicated an increased risk of haemorrhage of one-half to two-thirds.P Perhaps not unexpectedly, bleeding occurs more frequently with therapeutic rather than low-dose prophylactic heparin treatment. In one study of heparin used to prevent thromboembolism following spinal cord injury, seven out of 29 patients had evidence of bleeding in a group receiving heparin adjusted to prolong the APTf at least 1.5 times, compared with no bleeding events in a group receiving 5000 units twice daily as a fixed dose.t-Variation in the rates of haemorrhage in both randomized trials and cohort studies has prompted efforts to identify particular factors which influence haemorrhagic risk. As already indicated, these could include heparin dosage, as well as the biological responses (as measured by laboratory tests) and method of drug administration. In addition to these treatment factors, variation in patients resulting from demographic factors, underlying illnesses and concurrent medication have also been studied either by randomised trials or subgroup analysis of cohort studies.
Heparin dosage and response
There are no studies which have independently assessed the effects of heparin dosage and response, measured by in vitro coagulation tests such as the APTf. In addition, there are no randomized trials of different heparin dosage in the treatment of venous thromboembolism. Analysis of trials comparing methods of heparin administration shows that there is a correlation (r = 0.56) between mean daily heparin dosage and the rates of major haemorrhage observed. 15 A randomized controlled trial of thromboembolic prophylaxis'< discussed earlier revealed more bleeding with higher heparin dosages which prolonged the APTf than with the fixed lower doses (13 200 vs 5000 units twice daily).
The evidence supporting increased risk of bleeding corresponding to an increasing anticoagulant effect on in vitro tests is, however, conflicting. Norman and Provan'v detected five major bleeding episodes in ten patients in whom the APTf was prolonged to more than twice the upper limit of their therapeutic range for 50% or more of assays, compared to only one of 40 patients with APTT maintained in their target range throughout treatment. Landefeld et alJ? found the APTT to be useful as part of an index to estimate risk of major bleeding in hospitalized patients commencing anticoagulation. In contrast, Basu et al. found heparin dose and APTT to be similar in patients with or without bleeding,w whilst Pitney et al. reported bleeding despite laboratory tests remaining within an acceptable range. 19 Thus, while there is some support for increasing prolongation of the APTT and dosage of heparin as risk factors for bleeding, these are neither particularly sensitive nor specific measurements. As already indicated, bleeding may occur at any dose of heparin with APTT in the target range of 1.5-2.5 times control.
Method of administration
Six randomized trials lO • ll,2G--23 have compared continuous intravenous infusion with intermittent intravenous injection of heparin in the treatment of venous thromboembolism, Meta-analysis of these studies reveals an average incidence of major bleeding of 6.8% with continuous infusion and 14.2% with intermittent intravenous injection (p = 0.01).24 This difference may be due to the lower doses of heparin given to patients who received the continuous infusion, rather than an advantage inherent in the method. However, it seems plausible that at least part of the increase in bleeding might result from pulses of high plasma concentrations of heparin. In all six trials, the group receiving the higher daily dose had more bleeding complications (in five of the trials this was the group receiving intermittent treatment).
In addition, recent studies 25-30 have compared continuous intravenous heparin with therapeutic subcutaneous injection. A meta-analysis of eight such studies reported the incidence of major bleeding to be similar for both routes: 5.2% for continuous intravenous infusion and 4.1 % for subcutaneous injection (relative risk 0.79; 95% confidence intervals, 0.42-1.48).31
Low molecular weight heparin
At present low molecular weight (LMW) heparins are predominantly used in primary thromboprophylaxis; there is insufficient evidence to evaluate fully the risks of haemorrhage
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with regard to their use as 'formal anticoagulants'. Meta-analysis of randomized trials in primary thromboprophylaxis indicates that the risks of bleeding with LMW heparins are comparable to those with low-dose unfractionated heparin. 32 Other studies have reported no difference in the incidence of haemorrhage in patients given LMW heparin for similar indications compared to those given placebo. 33.34 Such data reflect the low overall incidence of haemorrhage when heparins are used for primary thromboprophylaxis. It remains to be seen whether the theoretical benefits of LMW heparins will be reflected in lower rates of haemorrhage when compared to unfractionated heparin at full therapeutic doses.
Patient factors
Wide variations in reported bleeding rates in different trials which used similar dosages and routes of administration of heparin imply that other factors than those related to treatment influence bleeding risk. Whilst risk factors are most reliably identified by randomized trials examining the variable in question, such data are often unavailable for practical or ethical reasons. Much of the information regarding patient factors comes from subgroup analysis of cohorts underguing anticoagulation. Risk factors suggested by this approach should be interpreted with caution, with allowance made for possible confounding variables.
Age and sex
The influence of age and sex on bleeding risk is controversial, because of the limitations of subgroup analysis which provides the basis of available evidence. The issues are important because of the expanding elderly population particularly at risk of thromboembolic disease.
Most studies examining age as a risk factor for heparin-induced bleeding have found more frequent bleeding in the elderly,1l, 17.18,20,35,36 although there are some small studies demonstrating no differences. 1o,16.32 Whether age acts as an independent, causal risk factor for bleeding, or as a covariant of other unidentified factors, has not been fully addressed. Whilst searching for these covariants may add discriminatory power to our ability to predict bleeding risk, it is easy to use age as a surrogate risk factor, so that it is likely that increasing age will remain a rela-tive contraindication to anticoagulant therapy. By the same token, age is a surrogate marker of thromboembolic disease and could equally be seen as a relative indication. Unfortunately most of the randomized trials demonstrating the overall benefits of anticoagulation in specific thromboembolic disorders are not directly applicable to elderly patients.
Some studies have indicated that elderly women are at higher risk of heparin-related bleeding than men 36.37 but this finding is inconsistent,to.II.I6-18.2o.21 with no readily available explanation, and may be an artefact produced by analysis of relatively small numbers.
Underlying disease
Recent surgery or trauma have been shown to be important and clinically relevant risk factors for bleeding during heparin therapy. Hull et al. 38 identified patients with proximal vein thrombosis as being at high or low risk for bleeding depending whether or not there was recent surgery or trauma. High-risk patients received a daily starting dose of 30 000 units of heparin by infusion, compared to 40 000 units received by the lowrisk group. Despite the lower heparin dosage, bleeding rates were 11% in the high-risk group compared to 1% in the low-risk group.
Liver dysfunction and worsening liver function during heparin therapy have been shown to be risk factors for bleeding.!? Heavy alcohol consumption was implicated as an independent risk factor for major, but not minor, bleeding during heparin therapy in the largest study of risk factors,35 although this has not been confirmed in other studies.
Most studies have found an increased frequency of intracranial haemorrhage in patients with underlying ischaemic cerebrovascular disease receiving anticoagulants. Although intracranial bleeding overall is rare, it is the commonest cause of fatal bleeding with anticoagulant therapy.39-44 While reducing the frequency of recurrent embolism in cardioembolic strokes, heparin increases the frequency and severity of haemorrhagic infarcts.v
Increased heparin-related bleeding has been reported in congestive cardiac failure.t? renal failure, carcinomatosis and severe anaemia. 17
Concurrent medication Aspirin
Aspirin usage in conjunction with heparin has been identified as a risk factor for bleeding. 11.16,35 In one study, aspirin increased operative blood loss in patients undergoing coronary artery bypass grafting who received high-dose heparin as part of the procedure. 46 This has been confirmed in other studies, although an increased rate of bleeding with concomitant aspirin usage has not been a universal finding.w-'? This issue is clearly of considerable clinical relevance to the acute management of ischaemic heart disease; in general, aspirin has been used without serious bleeding in combination with therapeutic doses of heparin.
Thrombolysis
The addition of heparin to thrombolytic therapy for myocardial infarction has been studied in several large randomized trials. 47~9 These demonstrated an increase in major or minor bleeding episodes with the combination compared to the use of thrombolytic agents alone, although no increase in rates of fatal bleeding or haemorrhagic stroke.
Warfarin
Warfarin is the most widely used of the coumarin anticoagulants, particularly in the UK. It is a competitive inhibitor of vitamin K in a vitamin K-dependent energy cycle, which powers a posttranslational modification of factors II, VII, IX and X in the liver, on which normal coagulation function depends. In the presence of warfarin, defective coagulant proteins are synthesized, an effect which can be monitored using the PT, which is dependent in part on normal activity of factors II, VII and X. The degree of prolongation of the PT in response to warfarin depends on the thromboplastin used to initiate the extrinsic coagulation pathway.>? Variation in the sensitivity of thromboplastins used worldwide means that similar PT ratios may reflect differing degrees of anticoagulation according to the thromboplastin used in the assay. Prothrombin ratios are converted to an international normalized ratio (INR) for the purposes of comparison between thromboplastins, and are reported as such in this review. The INR is calculated as (PT ratio)ISI, i.e. the prothrombin time ratio raised to the power of the International Sensitivity Index (lSI) of the thromboplastin used.>'
Bleeding on warfarin -absolute risks
Randomized trials comparing warfarin with placebo have been performed for the following indications: cerebrovascular disease, ischaemic heart disease, atrial fibrillation and hip surgery. Taken together, bleeding occurred in 14% of patients receiving warfarin compared to 3% taking placebo. The relative risks for fatal, major, and major or minor bleeding were 4.8, 6.6 and 4.0 respectively, compared to placebo. 12.52 Duration of therapy Randomized trials and inception cohort studies can be used to estimate the frequency of bleeding in relation to duration of treatment. Landefeld and Beyth, in a recent review,'2 calculated annual frequencies of 0.6%,3.0% and 9.6% respectively for fatal, major, and major or minor bleeding. Levine et al. estimated fatal, major and total bleeding risks to be 0.8%, 2% and 6% per year. 53 In addition to total duration of therapy, bleeding risk is probably greater during the initial phase of anticoagulation; in one study bleeding frequency decreased from 3.0% per month to 0.8% per month during the first year of therapy, and to 0.3% per month thereafter.e?
Wide variation in bleeding rates have been reported both between and within studies with differing indications for therapy. Treatment and patient factors have been implicated in determining the frequency, severity and site of bleeding. Such factors include intensity of
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anticoagulation, clinical indication for therapy, age, underlying or associated illness and use of other drugs.
Intensity of anticoagulant effect
The use of different thromboplastins in the determination of the prothrombin time led to (initially unrecognized) varying intensities of anticoagulation in different studies. In North America, where less-sensitive rabbit brain thromboplastin was used, more intense anticoagulation was achieved for a similar degree of prolongation of the PT. This makes comparison of bleeding rates between studies unreliable unless the thromboplastin sensitivity is known so that the INR can be calculated. Hull et al. 54 identified greater rates of haemorrhage in patients monitored with rabbit brain thromboplastin compared to those monitored with human thromboplastin. The similar therapeutic ranges and PT in both groups in fact corresponded to a range in the INR of 2.5-4.1 and 2.0-2.3, respectively. Three other randomized trials 5 5-57 support the relationship between intensity of anticoagulation (calculated as INR) and the risk of bleeding ( Table 1 ). Bleeding risk is increased approximately threefold in patients maintained at INR 3.0-4.5 compared to those at INR 2.0-3.0. Recent studiesi-« in patients with non-rheumatic atrial fibrillation lend support to the view that rates of haemorrhage can be reduced with continued protection against thromboembolism using a lower intensity of anticoagulation.
There is also evidence that severity as well as overall frequency of bleeding is increased with higher levels of anticoagulation. Forfar reported that 23 of 24 episodes of life-threatening haernor- 
Patient factors
Underlying disease When studies quoting bleeding rates are grouped according to the clinical indication for anticoagulation there is evidence of increased major bleeding in patients with cerebrovascular disease, venous thromboembolism and to a lesser extent ischaemic heart disease than in those with atrial fibrillation or prosthetic heart valves.V Rates of fatal haemorrhage, particularly intracranial, are highest amongst patients anticoagulated for ischaemic cerebrovascular disease. 39,41,52
Vascular diseases
Based on the information quoted showing higher risk of bleeding, it seems likely that concurrent cerebrovascular disease increases the risks of intracranial haemorrhage in patients anticoagulated for other indications.
Several studies have also implicated hypertension as a risk factor for intracranial haemorrhage during treatment with warfarin, particularly in patients with cerebrovascular disease. The strength of this association, when factors such as age, cerebrovascular or ischaernic heart disease are controlled for, is still uncertain. 39, 59, 60 Observational studies identified atrial fibrillation as a marker of increased bleeding risk,39,59 in contrast to the low rates of haemorrhage in recent primary prevention trials. 1-6 This may be a reflection of the lower intensity of anticoagulation used recently, and of differences in bleeding risk arising from the original indication for treatment. In the older, observational studies, atrial fibrillation was likely to be a covariant of other indications such as cerebrovascular disease rather than the indication for treatment per se. Even in subjects with recent cerebrovascular events and atrial fibrillation, the overall benefits of anticoagulation for atrial fibrillation have been shown in a recent randomized trial of secondary prevention of stroke."
Gastrointestinal and genitourinary diseases
Previous gastrointestinal bleeding has been associated with an increased risk of subsequent bleeding on warfarin.'? although not with a history of peptic ulceration alone, 39, 60 Blood loss from the gastrointestinal or genitourinary tract during anticoagulant therapy is strongly associated with the presence of underlying lesions, often previously undiagnosed. 58,61-66 One study of investigation of gastrointestinal bleeding occurring during anticoagulant therapy revealed unknown, underlying lesions in a third of cases; of these about a half were malignant.s-Some evidence suggests that bleeding with a therapeutic PT is more likely to be related to a specific undiagnosed lesion than bleeding with an abnormally prolonged PT. However, gastrointestinal or genitourinary bleeding with INR >7.5 can still reveal a significant number of lesions if investigation is pursued.s-As a result, therefore, such bleeding should be investigated in most cases, whatever the degree of anticoagulation.
There is a lack of evidence concerning the effect of liver disease on bleeding risk with oral anticoagulants, reflecting clinicians' reluctance to contemplate such therapy in these patients. The evidence of increased in-hospital bleeding'? suggests this reluctance is well founded.
Studies using medical records to determine the presence of alcoholism have not demonstrated increased bleeding risks on warfarin. 17,39, 60 The accuracy of this technique has been questioned, particularly in view of the implication of heavy alcohol use as a risk factor for heparin-related major bleeding. 35
Other concurrent illness
Recent myocardial infarctions? and congestive cardiac failures? have been associated with major bleeding in warfarinized outpatients, as have renal failure and severe chronic anaernia.w
Age
There is even less consensus regarding the role of age in warfarin-related bleeding than for heparin. Two inception-cohort studies have demonstrated increased bleeding risk in elderly patients,39,60 whilst other cohort studies have reported conflicting results. 44,58,61,67,68 Landefeld et al. estimated the relative risk of major bleeding to be 3.2 for patients aged 65 years or 01der 39; this variable was subsequently used in the validation of a predictive model of risks of bleeding in warfarinized outpatients with some success.s-This issue has not been adequately assessed with regard to the overall risk-benefit equation for elderly patients in the randomized trials so far conducted.
Other drugs -aspirin
Randomized trials of the addition of aspirin to oral anticoagulants in patients with prosthetic heart valves have demonstrated an increase in rates of haemorrhage. 6 9--71 The increase in rates of fatal and major haemorrhage in most of these studies has significantly offset the reductions in thromboembolic events. However, a recent study using lower doses of aspirin (100 mg/day) demonstrated no increase in fatal or major haemorrhage compared to anticoagulants alone, with a small increase in bleeding events overall. The overall benefits of the combination remained considerable, with a 61% reduction in systemic embolism, fatal or intracranial haemorrhage, and vascular death combined.P
General principles of bleeding risk
Recent randomized trials have extended the indications for anticoagulation into new areas, bringing increased bleeding risks in terms of numbers of patients and the scale of risk to the individual by virtue of the treatment and patient characteristics at issue in the studies. Thus, there are now indications for the anticoagulation of stroke patients with atrial fibrillation (despite risks of haemorrhage in recent infarcts), for primary stroke prevention in atrial fibrillation (large numbers of often elderly patients) and perhaps the addition of aspirin to warfarin for patients with prosthetic heart valves (with the resultant increased risk of gastrointestinal haemorrhage). To these could be added the use of high-intensity anticoagulation after interventional cardiology and angiology.
The trials emphasize that risk assessment cannot be undertaken in isolation; indeed, many demonstrate that there are overall benefits of anticoagulation even for high-risk patients. Such patients do not deserve to miss out on consideration of the benefits of anticoagulation. Equally, however, an individual's risk of bleeding is important in determining their likelihood of benefit; in this respect, identification of factors affecting bleeding risk may aid the prediction of risk and severity of bleeding.
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Estimating the risk of bleeding based on the features already identified may be aided by the use of a multivariate model to construct a 'bleeding index' and stratify risk. Both inpatient 17 ,73 and outpatient indices 39 ,62 of bleeding risk have been developed using previously identified features from inception cohort studies and validated in single-centre studies, In one example, the independent risk factors identified for bleeding during outpatient warfarin therapy were'": 1) age> 65 years; 2) a history of stroke; 3) a history of gastrointestinal bleeding; 4) one or more of three concurrent illnesses:
renal failure, recent myocardial infarction, and severe anaemia; 5) atrial fibrillation.
The index was subsequently validated by its application to a further cohort of patients stratified accordingly as high, medium or low risk. Rates of major bleeding at 48 months were 63%, 17% and 2%, respectively. In addition, the PT and the time since starting therapy were independently associated with risk of major bleeding.s-The identification of subjects at greater bleeding risk may allow for more appropriate targeting of anticoagulants and perhaps more careful monitoring of therapy. Guideline-based anticoagulation based on individual risk-benefit assessment, with daily follow-up and reassessment of recommendations, has been shown in a single-centre randomized study to be effective in reducing major bleeding events in medium-or high-risk patients compared to those receiving 'usual care',74 Such results should be reproduced before firm conclusions are drawn, but may indicate the need for better and wider application of what we already know rather than for further research.
The identification of treatment-related factors also has predictive value, but may be more useful in modifying bleeding risks. Many patient factors cannot be modified by the clinician and anticoagulants are either pres~ribed or withheld appropriately. Features relating to the duration, intensity and monitoring of treatment may be amenable to modification and show promise for the future. The duration of heparin therapy has been the subject of a study which indicates that a five-day course with warfarin administered immediately is as beneficial as previous conventional ten-day heparin therapy for the treatment of proximal deep vein thrombosis. 38 In view of the daily risk of bleeding on heparin the shorter period of therapy should result in a reduction in bleeding risk.
Monitoring of the anticoagulant effects of warfarin may be improved by the development of portable self-monitoring PT time devices,75.76 or of newer, more refined, in vitro coagulation assays.?? Although both techniques show promise in improving overall coagulation control, neither has yet been shown to reduce bleeding complications.
Most promise in the field of reducing bleeding risk has been shown in studies using less intense anticoagulant regimes, either alone or in combination with low-dose aspirin. Initially it was demonstrated that less intense anticoagulation, with INR of around 2.0, was as effective as more conventional and intense treatment in the treatment of proximal vein thrombosis, but with a reduction in bleeding events. 54 A similar degree of efficacy, with reduction in haemorrhage risk, has been confirmed in prosthetic heart valve studies 55-57 and has been extended in the recent studies of atrial fibrillation. It seems reasonable for most indications to aim for an INR in the range 2.0-3.0 based on current evidence.P In addition, some recent evidence supports the use of low-dose aspirin in combination with warfarin in improving overall outcome without worsening severe haemorrhagic risk for prosthetic heart valve patients.P These approaches of low dose (75-150 mg) aspirin in combination with low-dose or even fixed minidose warfarin (l mg/day) are currently under evaluation in ongoing studies. Such studies, based on modifying identified risk factors for bleeding, should improve the risk-benefit equation for the population and the individual undergoing anticoagulation.
Summary

Heparin
Conventional heparin at therapeutic doses increases risk of haemorrhage. Length of treatment with heparin appears to be an important determinant of cumulative risk of bleeding, with less conclusive evidence to support the effects of higher daily doses or greater prolongation of the APTf ( Table 2) . Continuous intravenous infusion and intermittent subcutaneous injection are likely to be equally safe methods of administration. Recent trauma, liver dysfunction and cerebrovascular disease (in the case of intracranial bleeding) are recognized risk factors for major or life-threatening haemorrhage. The presence of other serious underlying illnesses as well as combination with other anti thrombotic agents increases bleeding risk. Elderly patients seem to be at increased haemorrhagic risk compared with younger patients but, conversely, may have more to gain from therapy.
Warfarin
Bleeding risk is increased by either inpatient or outpatient warfarin therapy. There is some evidence that bleeding risk is greater for inpatients, but that the risk of bleeding is less for patients treated with warfarin than for those on heparin. Whether this is related to patient characteristics or a greater prohaemorrhagic effect of heparin compared to warfarin is unclear. Cumulative bleeding rates increase with the duration of warfarin therapy, although risks are probably greatest during the initiation of treatment (Table  3 ). There is good evidence that haemorrhagic risk is influenced by the intensity of anticoagulation, the additional use of aspirin and the nature of the presenting and associated disorders. Previous stroke or gastrointestinal bleeding increase bleeding risk, as do the presence of other serious illnesses. Lesions in the gastrointestinal and genitourinary tracts are responsible for a large proportion of bleeding, which therefore warrant investigation. The relationship between factors such as age, hypertension and bleeding risk is unclear through the nature of the studies; increasing age and hypertension may be useful markers, both of risk of bleeding and risk of thromboembolism.
